axSpA | axPsA clinical definition | P value for comparison of axSpA with psoriasis and axPsA with positive clinical definition | axPsA imaging definition | P value for comparison of axSpA with psoriasis and axPsA with positive imaging definition | |||||
With psoriasis | Without psoriasis | Positive | Negative | Positive | Negative | Not performed | |||
n | 181 | 1247 | 297 | 1098 | 196 | 384 | 815 | ||
Female gender, n (%) | 76 (42) | 561 (45) | 177 (60) | 642 (58) | <0.0001 | 111 (57) | 243 (63) | 465 (57) | 0.005 |
Age, mean (SD) | 47.3 (13.1) | 43.8 (13) | 50.8 (11.4) | 52.4 (12.5) | 0.001 | 52 (12) | 51.8 (11.7) | 52.2 (12.7) | <0.001 |
School education ≥10 years, n (%) | 123 (75) | 896 (82) | 196 (77) | 767 (79) | 0.663 | 129 (75) | 266 (78) | 568 (79) | 0.928 |
Smoking, current, n (%) | 68 (42) | 427 (39) | 85 (34) | 272 (29) | 0.081 | 62 (37) | 101 (30) | 194 (28) | 0.303 |
Symptom duration, mean (SD) | 14.7 (12.1) | 11.3 (10.6) | 10.7 (10.4) | 8.7 (8.7) | <0.001 | 11.2 (10.1) | 10.1 (9.1) | 8.2 (8.8) | 0.003 |
Disease duration, mean (SD) | 8 (10.1) | 6.7 (9) | 6.8 (8.2) | 6 (7.1) | 0.178 | 7 (7.3) | 6.7 (7.1) | 5.7 (7.4) | 0.291 |
HLA-B27 not done, n (%) | 15 (8) | 59 (5) | 83 (28) | 483 (44) | not done | 51 (26) | 118 (31) | 397 (49) | not done |
HLA-B27 positive (of valid values), n (%) | 111 (67) | 901 (76) | 48 (23) | 102 (17) | <0.0001 | 35 (24) | 41 (15) | 74 (18) | <0.001 |
CRP mg/L, mean (SD) | 10.2 (16) | 12.3 (17.2) | 8.3 (12.5) | 9 (13.4) | 0.30 | 6.7 (10.3) | 8.8 (12.8) | 9.5 (14) | 0.574 |
CRP ≥5 mg/L, n (%) | 67 (40.9) | 580 (54.7) | 106 (39.1) | 412 (42.6) | 0.72 | 73 (41.5) | 152 (42.3) | 293 (41.7) | 0.908 |
BMI, mean (SD) | 28.3 (5.4) | 26.7 (5.1) | 28.9 (6.1) | 29 (6) | 0.236 | 28.4 (5.8) | 29.3 (6.3) | 29 (5.9) | 0.875 |
Obesity (BMI ≥30), n (%) | 56 (33) | 296 (24) | 103 (35) | 422 (39) | 0.648 | 61 (32) | 146 (39) | 318 (40) | 0.839 |
Peripheral manifestations, n (%) | 63 (35) | 440 (35) | 250 (84) | 998 (91) | <0.001 | 175 (89) | 339 (88) | 734 (90) | <0.001 |
Uveitis, ever, n (%) | 26 (14) | 192 (15) | 12 (4) | 15 (1) | <0.001 | 7 (4) | 9 (2) | 11 (1) | <0.001 |
IBD, ever, n (%) | 13 (7) | 80 (6) | 13 (4) | 13 (1) | 0.185 | 8 (4) | 9 (2) | 9 (1) | 0.186 |
Physician global disease activity (NRS), mean (SD) | 5.5 (2.2) | 5.3 (1.9) | 5.5 (1.9) | 5 (1.9) | 0.917 | 5.4 (1.9) | 5.2 (1.9) | 4.9 (1.9) | 0.744 |
Patient global disease activity (NRS), mean (SD) | 5.5 (2.5) | 5.8 (2.4) | 5.9 (2.4) | 5.7 (2.4) | 0.145 | 5.8 (2.3) | 6 (2.3) | 5.6 (2.4) | 0.341 |
Patient pain (NRS), mean (SD) | 5.6 (2.5) | 5.6 (2.3) | 5.7 (2.4) | 5.5 (2.4) | 0.658 | 5.7 (2.3) | 5.8 (2.4) | 5.4 (2.4) | 0.795 |
Sleep disorder (NRS), mean (SD) | 5.7 (2.9) | 5.3 (3) | 5.6 (3.1) | 4.7 (3) | 0.614 | 5.4 (3.1) | 5.4 (3) | 4.5 (3) | 0.335 |
PsA patients are included twice, once in the respective clinical definition column and once in the respective imaging definition column.
axPsA, axial PsA; axSpA, axial spondyloarthritis; BMI, body mass index; CRP, C reactive protein; IBD, inflammatory bowel disease; NRS, Numeric Rating Scale; PsA, psoriatic arthritis.